Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference
Newsfile Corp•05/10/2026•07:00 ET
1
Key Highlights
- ➤Phio to present INTASYL platform and PH-762 development update at NIBA conference October 7, 2026
- ➤PH-762 lead program targets cutaneous squamous cell carcinoma as a potential non-surgical treatment
- ➤Phase 1b trial evaluated PH-762 in cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma
- ➤Activities supporting PH-762’s next clinical-development phase expected to be completed during first quarter 2027
Expert Statements
Robert Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals
“NIBA provides an excellent forum to communicate Phio's investment thesis based on a differentiated siRNA therapeutic platform designed to enhance immune-cell function in solid tumors with a strong safety profile”
Highlighting its Proprietary INTASYL siRNA Therapeutic Platform and Development Update for Lead PH-762 Program in Cutaneous Squamous Cell Carcinoma
King of Prussia, Pennsylvania--(Newsfile Corp. - October 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced that it has accepted the invitation to present at the National Investment Banking Association's (NIBA) 153rd Conference on October 6-7, 2026, in Fort Lauderdale, Florida.
Get started
Create a free account to read the full story.